First Phosphate Announces Intention to Complete $2,000,000 Non-Brokered Private Placement to Strategic Investor. The gross proceeds from the Flow-Through Offering are to be used to incur “Canadian exploration expenses”
Author: Dan Brody
Saguenay, Quebec–(Newsfile Corp. – June 25, 2025) – First Phosphate Corp. (CSE: PHOS) (OTCQB: FRSPF) (FSE: KD0) (“First Phosphate” or the “Company”) is pleased to announce that a 5,000-kilogram bulk sample has been drilled and collected at its Bégin-Lamarche phosphate project, located in the Saguenay-Lac-Saint-Jean region of Quebec, Canada. The purpose of the bulk sample is to conduct advanced metallurgical testing to refine the process for recovery of apatite (phosphate), magnetite (iron), and ilmenite (titanium). This work follows the successful preliminary metallurgical testing conducted in June 2023, which confirmed the positive recovery of the targeted minerals. These tests demonstrated the technical…
BioVaxys Technology Corp. is developing its patented DPX™ platform to address the challenges of lipid nanoparticles (LNPs) in mRNA vaccine delivery. Learn how DPX improves stability, immune responses, and manufacturing economics as the mRNA vaccine market projects $48 billion growth by 2030.
GivBux (OTC: GBUX), a publicly traded super app and charitable giving platform, is creating a sharing economic community of brands. The app provides consumers with an easier and more convenient way to shop and buy, as well as merchants a more efficient and profitable way to advertise.
BioVaxys Secures GMP-Grade Lipid Supply for Production of DPX-Based Vaccines in Advance of Preclinical and Clinical Program Ramp-Up VANCOUVER, BCDecember 17th, 2024BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys” or the “Company”) is pleased to announce that in anticipation of restarting clinical studies of various DPX formulations and initiating new preclinical studies, it has acquired a 48-kilogram (“kg”) supply of GMP-grade lipid to enable production of the Company’s DPX antigen packaging delivery platform. These unused lipids from the former IMV, Inc., had been previously produced in advance of anticipated IMV clinical studies and commercial ramp up. In February…
BioVaxys Shares New Data on its DPX™ Immune Educating Platform at Personalized Cancer Vaccine Summit DPX Formulations Superior to Mixing with Commonly Used Adjuvants DPX Without Antigen Cargo Has Immune Stimulating Properties Unique Potential for DPX in New Fields of Use VANCOUVER, BCDecember 5, 2024 — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys” or the Company”) presented a new study today at the Personalized Cancer Vaccine Summit (formerly known as the mRNA Cancer Vaccine Summit) in Boston, MA, that supports further differentiation of its DPX immune educating platform from current aqueous, emulsion, and LNP antigen delivery systems. …
Saguenay, QuebecDecember 2, 2024First Phosphate Corp. (CSE: PHOS) (OTCQB: FRSPF) (FSE: KD0) (“First Phosphate” or the “Company”) is pleased to announce that it has signed a technology license agreement (“TLA”) with Prayon SA of Engis, Belgium (“Prayon”) for the technology to produce merchant grade phosphoric acid (MGA) from igneous apatite phosphate rock as well as high-purity gypsum. Prayon will grant First Phosphate a license to use its technology to design, build, operate and maintain, within Canada, a Merchant Grade phosphoric acid (MGA) manufacturing plant with a production capacity of six hundred (600) metric tons of product per day of P2O5 (phosphate).…
MADISON, WINovember 20th, 2024 BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys”) and SpayVac for Wildlife, Inc. are pleased to jointly announce that SpayVac for Wildlife, Inc.’s Madison, Wisconsin laboratory and production facility is now fully able to supply its cutting-edge contraceptive vaccines, including its well-established pZP vaccine (“SpayVac®”) and its newest GnRH vaccine for commercial aquaculture and other species. The scaled-up production capacity will support wider SpayVac availability for field trials and market seeding studies, the production ramp-up in preparation for a SpayVac launch in the near future, as well as new antigen formulations tailored for diverse…
BioVaxys to Participate in the US Government Biomedical Advanced Research and Development Authority (BARDA) Rapid Response Partnership Vehicle (RRPV) Vaccine Development Consortium VANCOUVER, BCNovember 5th, 2024Press Release– BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys” or the “Company”) is pleased to announce that it has been invited to and joined The Rapid Response Partnership Vehicle (RRPV), a consortium of large and small biopharma, contractors, government agencies, and academic and non-profit research institutions that support the US Government’s Biomedical Advanced Research and Development Authority (BARDA) in its objective to accelerate Medical Countermeasure product and technology development to address evolving…
Study [KK1] Results Position Company to Target Segments of $270B+ Multi-Billion Dollar Drug Delivery Systems Market1 VANCOUVER, BC, October 31st, 2024 — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys” or the “Company”) highlights studies showing that its novel immune educating delivery platform, DPX™, recruits and activates unique subsets of antigen-presenting cells (“APCs”) to drive immunogenicity of antigens, and exhibits superior immune activation compared to aqueous and emulsion-based antigen delivery systems. With cancer vaccines, the successful eradication of tumors relies on the persistent delivery of antigenic APCs to prime potent, antigen specific, cytotoxic T cells. Current peptide antigen delivery…